Project Grant K99GM154060

Award Date 7/1/24
Completion Date 6/30/26
Dollars Obligated $125K
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Stanford, CA 94305, USA
Similar Awards
This Project Grant award from the National Institutes of Health (NIH) under the Research Infrastructure Programs (CFDA 93.351) provides $222,750 to the University of Alabama at Birmingham (UAB) to develop innovative tools for investigating the composition and dynamics of the ciliary proteome. The project aims to create engineered mouse and cell-based models that enable temporal and cell type-specific labeling of proteins in the ciliary transition zone, a critical regulatory gate for protein...
This Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) provides $1,808,868.00 to the University of Alabama at Birmingham (UAB) to conduct research on the mechanisms of ciliopathy-associated structural birth defects. The key objectives of this 5-year project are to: 1) identify and characterize genetic variants of interest in known and novel ciliopathy genes, 2) assess the pathogenicity...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,063,324 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Tulane University to support research on CD4+ T cell immunity in the respiratory tract. The grant aims to shed new light on pulmonary host defenses that can be leveraged to reduce the global burden of pneumonia mortality and morbidity. Using murine and primate respiratory tract samples, the research will assess the metabolic requirements of lung and nasal...
This Project Grant award of $701,440 from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research at Yale University to investigate the function of the RUVBL1-RUVBL2 proteins in the assembly of dynein arms, which are critical components of motile cilia. The research aims to elucidate the mechanism of RUVBL1-RUVBL2 foci formation and systematically define the components and biochemical relationships of the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $659,341 to The Children's Hospital of Philadelphia (CHOP) to conduct research on the regulation of lung innate lymphoid type 2 (ILC2) cells during helminth (parasitic worm) infections. The key objectives of this 5-year research project are to: 1) Determine how the E3 ubiquitin ligase CUL5 impacts the clearance of...
This Project Grant award of $424,338.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program supports research to elucidate the mechanisms of ependymal ciliary signaling. The primary focus is to define the complement of G protein-coupled receptors (GPCRs) expressed in ependymal cilia and determine how GPCR activation impacts cilia beating and...
The Project Grant award R03TR005313, funded by the National Center for Advancing Translational Sciences (NCATS) under CFDA program 93.350, is focused on characterizing the physiological role and biophysical properties of the chloride intracellular channel 2 (CLIC2) protein. The $157,500 award to The Ohio State University aims to establish the impact of CLIC2 mutations on cardiomyocyte differentiation and function, as well as the role of CLIC2 in regulating calcium homeostasis. The research...
This $750,162 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund research by The Children's Hospital of Philadelphia (CHOP) to investigate the role of lymphatic dysfunction in the development of post-lung transplant complications. The key objectives of this 4-year project include: 1) determining the mechanisms of lymphatic vascular function after lung transplantation, 2) evaluating...
The National Science Foundation (NSF) Division of Molecular and Cellular Biosciences awarded Emory University a $724,356 Project Grant under the Biological Sciences program (CFDA 47.074) to investigate the role of the protein ARL13B in controlling ciliary cyclic AMP (cAMP) signaling. The research aims to unravel the ciliary cAMP "signature", optogenetically stimulate cAMP signaling within normal and ARL13B-excluded cilia, investigate the role of ciliary cAMP signaling in remodeling...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $781,685 in funding to The Children's Hospital of Philadelphia (CHOP) to conduct research on the molecular circuits controlling human T follicular regulatory (Tfr) cell development. The key objectives are to establish the lineage and function of different Tfr cell subsets, examine their localization within...

TULP3 INTEGRATES ESSENTIAL CILIARY FUNCTIONS - PROJECT SUMMARY PRIMARY CILIA PLAY A PIVOTAL ROLE IN HUMAN HEALTH, ACTING AS SIGNALING HUBS TO SENSE EXTRACELLULAR CUES SUCH AS ODORANTS, METABOLITES, LIGHT, NEUROTRANSMITTERS, AND MORE. DEFECTS OR FAILURE OF THESE SIGNALING HUBS TO FUNCTION LEADS TO DEVELOPMENTAL DISORDERS, IMMUNE DYSFUNCTION, DIABETES, OBESITY, PARKINSON'S DISEASE, CANCER, AND OTHER PATHOLOGIES. AN EARLY FOCUS OF THIS GRANT IS THE GENERATION OF BETTER TOOLS TO DISSECT PRIMARY CILIA FUNCTION AND MECHANISM, SUCH AS A PROTOCOL FOR SYNCHRONIZED CILIOGENESIS IN HUMAN RETINAL PIGEMENTED EPITHELIAL (RPE) CELLS COUPLED WITH MICROSCOPY AND SHOTGUN/PHOSPHOPROTEOMIC MASS SPECTROMETRY, TO DISSECT SIGNALING EVENTS TEMPORALLY AND SPATIALLY. WHILE MAPPING CILIOGENESIS VIA IMMUNOFLUORESCENCE WITH KNOWN MARKERS OF THE STAGES, ONE PROTEIN THAT EMERGED AS A STRONG CANDIDATE FOR REGULATING INTERPATHWAY COMMUNICATION WAS TULP3, A 50KDA CILIARY PROTEIN WHOSE PRIMARY KNOWN FUNCTION IS IN DRIVING THE IMPORT OF CILIARY GPCRS THROUGH UNCLEAR MECHANISMS. A COMBINATION OF SYNCHRONIZATION AND CLASSICAL CELL BIOLOGICAL APPROACHES WERE USED TO UNCOVER NOVEL PHENOTYPES REVEALING TEMPORAL AND SPATIAL TIMING OF TULP3'S FUNCTION IN GPCR TRAFFIC AS WELL AS NEW FUNCTIONS IN CILIOGENESIS, DOWNSTREAM OF TTBK2 RECRUITMENT BUT BEFORE AXONEME PROTRUSION. PATIENT MUTATIONS WERE IDENTIFIED FROM THE USE OF GWAS DATABASES TO PROBE FOR LINKS BETWEEN PROTEIN FUNCTION AND HUMAN HEALTH. CONSTITUTIVE EXPRESSION OF THESE TULP3 MUTANTS IN TULP3 KO BACKGROUND GENERATED NEW TOOLS TO PERTURB SELECT FUNCTIONS FOR TULP3, WHICH IS ESPECIALLY POWERFUL FOR PROBING FUNCTION-SPECIFIC BINDING DOMAINS AND PARTNERS. THIS PROPOSAL TESTS THE FOLLOWING HYPOTHESES: TULP3 (I) REGULATES RECEPTOR TRAFFIC PRIOR TO CARGO ARRIVAL AT THE BASAL BODY AND COUPLING TO IFT MACHINERY TO MEDIATE RECEPTOR ENTRY INTO CILIA AND (II) LICENSES AXONEMOGENESIS. FURTHERMORE, PRIMARY CILIA PERFORM TWO DIFFERENT FUNCTIONS IN LYMPHOID TISSUES: REGULATING FATE CHANGE OF HEMATOPOIETIC STEM CELLS INTO LYMPHOCYTES IN THE BONE MARROW, AND IN THE LYMPH NODE FACILITATING LYMPHOCYTE MATURATION. THESE HYPOTHESES WILL BE TESTED IN THE FOLLOWING AIMS: AIM 1- DETERMINE THE MECHANISM BY WHICH TULP3 MEDIATES MEMBRANE RECEPTOR TRANSPORT INTO CILIA. AIM 2- IDENTIFY THE FUNCTION AND MECHANISM OF TULP3 IN CILIOGENESIS. AIM 3- UNCOVER THE FUNCTION OF PRIMARY CILIA AND TULP3 IN THE GENERATION OF WHITE BLOOD CELLS. THESE AIMS WILL BE ADDRESSED USING CELL CULTURE AND MOUSE MODEL SYSTEMS TO PROBE TULP3 FUNCTION AND ITS ROLE IN IMMUNITY IN BOTH IN VITRO AND IN VIVO CONTEXTS. THE SUCCESS OF ANY AND ALL OF THESE AIMS WILL PROVIDE NOVEL INSIGHT INTO KEY MECHANISMS DRIVING CILIARY FUNCTION AND REVEAL CELLULAR CONTEXTS FOR HOW DISRUPTED IMMUNE FUNCTION ARISES. THE STUDY OF PRIMARY CILIA IN THE LYMPHATIC SYSTEM IS LARGELY UNCHARTED TERRITORY. AS A RESULT, THESE STUDIES ARE EXPECTED TO OPEN NEW FIELDS OF INVESTIGATION INTO MECHANISMS OF IMMUNE REGULATION.

Posted 6/6/24, 12:00 AM